By Dominic Chopping 
 

STOCKHOLM--Danish pharmaceutical company Genmab A/S (GEN.KO) said Wednesday that net sales of leukemia drug Arzerra (ofatumumab) during the third quarter of 2014 were GBP13.8 million.

This figure consists of net sales in the US of GBP5.3 million and in the rest of the world of GBP8.5 million.

Under the terms of the collaboration with GlaxoSmithKline (GSK), Genmab expects to receive a royalty payment of approximately DKK27 million.

The rest of world sales for the third quarter were enhanced by sales related to the supply of ofatumumab for clinical trials run by other companies.

-Write to Dominic Chopping at dominic.chopping@wsj.com; Twitter: @WSJNordics

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Gsk (LSE:GSK)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Gsk Charts.
Gsk (LSE:GSK)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Gsk Charts.